Related Experiment Video
Updated: Feb 19, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Paeoniflorin inhibits VSMCs proliferation and migration by arresting cell cycle and activating HO-1 through MAPKs and
Weifeng Li1, Wenbing Zhi1, Fang Liu1
1School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, PR China.
Abstract:
The proliferation, migration and inflammation of vascular smooth muscle cells (VSMCs) contributes to the pathogenesis and progression of atherosclerosis. Paeoniflorin (PF) as active compound in the Rhizoma Atractylodes macrocephala has been used for various diseases like cancer, splenic asthenia, anaphylaxis and anorexia. This study aimed to explore whether and how PF regulated the inflammation, proliferation and migration of VSMCs under ox-LDL stimulation. Here, we found that PF dose-dependently inhibited ox-LDL-induced VSMCs proliferation and migration, and decreased inflammatory cytokines and chemokine overexpression. Mechanistically, PF prevented p38, ERK1/2 and NF-κB phosphorylation, and arrested cell cycle in S phase. Meanwhile, PF regulated the HO-1 and PCNA expression. Furthermore, PF blocked the foam cell formation in macrophages induced by ox-LDL. These results indicate that PF antagonizes the ox-LDL-induced VSMCs proliferation, migration and inflammation through activation of HO-1, cell cycle arrest and then suppression of p38, ERK1/2/MAPK and NF-κB signaling pathways.
Insights
Paeoniflorin (PF) inhibits vascular smooth muscle cell proliferation, migration, and inflammation induced by oxidized LDL (ox-LDL). This natural compound also prevents foam cell formation, offering potential therapeutic benefits for atherosclerosis.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Cell Biology
Background:
- Atherosclerosis involves vascular smooth muscle cell (VSMC) proliferation, migration, and inflammation.
- Oxidized low-density lipoprotein (ox-LDL) is a key factor in atherosclerosis pathogenesis.
- Paeoniflorin (PF), derived from Rhizoma Atractylodes macrocephala, has diverse medicinal applications.
Purpose of the Study:
- To investigate the effects of PF on VSMC behavior under ox-LDL stimulation.
- To elucidate the underlying molecular mechanisms of PF's action.
- To assess PF's impact on ox-LDL-induced foam cell formation in macrophages.
Main Methods:
- VSMC proliferation, migration, and inflammatory cytokine/chemokine expression assays.
- Western blotting to analyze p38, ERK1/2, NF-κB phosphorylation, HO-1, and PCNA.
- Cell cycle analysis.
- Macrophage foam cell formation assay.
Main Results:
- PF dose-dependently inhibited ox-LDL-induced VSMC proliferation and migration.
- PF reduced inflammatory cytokine and chemokine levels.
- PF suppressed p38, ERK1/2, and NF-κB phosphorylation, arresting cell cycle in S phase.
- PF regulated HO-1 and PCNA expression and blocked macrophage foam cell formation.
Conclusions:
- PF exhibits anti-atherosclerotic properties by inhibiting VSMC dysfunction and inflammation.
- PF acts through HO-1 activation, cell cycle arrest, and suppression of MAPK and NF-κB pathways.
- PF demonstrates potential as a therapeutic agent for atherosclerosis treatment.
More Related Videos
09:39Quantitative Immunofluorescence Assay to Measure the Variation in Protein Levels at Centrosomes
Published on: December 20, 2014
12:00Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
Published on: July 5, 2017
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity
MAPK Signaling Cascades
Cancer Cell Migration through Invadopodia
Regulation of Angiogenesis and Blood Supply
cAMP-dependent Protein Kinase Pathways